PH22622A - Kit for use in the treatment of osteoporosis - Google Patents

Kit for use in the treatment of osteoporosis

Info

Publication number
PH22622A
PH22622A PH32203A PH32203A PH22622A PH 22622 A PH22622 A PH 22622A PH 32203 A PH32203 A PH 32203A PH 32203 A PH32203 A PH 32203A PH 22622 A PH22622 A PH 22622A
Authority
PH
Philippines
Prior art keywords
regimen
daily doses
osteoporosis
treatment
bone
Prior art date
Application number
PH32203A
Other languages
English (en)
Inventor
Vernon Albert Uchtman
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PH22622A publication Critical patent/PH22622A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Debugging And Monitoring (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH32203A 1984-04-30 1985-04-29 Kit for use in the treatment of osteoporosis PH22622A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60554084A 1984-04-30 1984-04-30
US68456084A 1984-12-21 1984-12-21

Publications (1)

Publication Number Publication Date
PH22622A true PH22622A (en) 1988-10-28

Family

ID=27084976

Family Applications (1)

Application Number Title Priority Date Filing Date
PH32203A PH22622A (en) 1984-04-30 1985-04-29 Kit for use in the treatment of osteoporosis

Country Status (12)

Country Link
EP (2) EP0381296B1 (de)
JP (1) JPH0655675B2 (de)
AT (2) ATE114473T1 (de)
AU (1) AU584611B2 (de)
CA (1) CA1277233C (de)
DE (2) DE3587956T2 (de)
DK (1) DK173735B1 (de)
FI (1) FI851686L (de)
HK (1) HK46694A (de)
IE (1) IE66497B1 (de)
NZ (1) NZ211925A (de)
PH (1) PH22622A (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
GR861167B (en) * 1985-05-02 1986-09-30 Research Corp Bone targeted inhibitors of carbonic anhydrase
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
ATE119777T1 (de) * 1991-02-26 1995-04-15 Procter & Gamble Pharma Behandlungsmethoden für osteoporose.
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
AU686458B2 (en) * 1994-09-09 1998-02-05 Procter & Gamble Company, The Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
FR2727629A1 (fr) * 1994-12-06 1996-06-07 Sanofi Sa Trousse pour cycle de traitement de l'osteoporose
ES2262145T3 (es) * 1994-12-28 2006-11-16 Gador S.A. Composicion anabolica para la masa osea que comprende olpadronato.
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
EP1158987A1 (de) * 1999-03-05 2001-12-05 The Procter & Gamble Company Verfahren zur erhohung des knochenvolumens mittels nicht natürlich vorkommenden fp agonisten und antiresorptiva
ES2394211T3 (es) 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
EP1317247A1 (de) * 2000-09-13 2003-06-11 The Procter & Gamble Company Kosmetisches verfahren zur behandlung der haut und/oder haare
HUE060822T2 (hu) 2006-12-29 2023-04-28 Ossifi Mab Llc Módszerek a csontnövekedés megváltoztatására SOST vagy WISE antagonista vagy agonista adásával

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
US4330537A (en) * 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis

Also Published As

Publication number Publication date
DE3587956T2 (de) 1995-05-24
JPS6133117A (ja) 1986-02-17
HK46694A (en) 1994-05-20
DE3583887D1 (de) 1991-10-02
CA1277233C (en) 1990-12-04
ATE114473T1 (de) 1994-12-15
EP0162510A1 (de) 1985-11-27
AU4176985A (en) 1985-11-07
DK193585A (da) 1985-10-31
AU584611B2 (en) 1989-06-01
IE66497B1 (en) 1996-01-10
EP0381296A1 (de) 1990-08-08
JPH0655675B2 (ja) 1994-07-27
NZ211925A (en) 1989-01-06
DE3587956D1 (de) 1995-01-12
DK193585D0 (da) 1985-04-30
ATE66608T1 (de) 1991-09-15
FI851686A0 (fi) 1985-04-29
DK173735B1 (da) 2001-08-20
EP0162510B1 (de) 1991-08-28
EP0381296B1 (de) 1994-11-30
IE851084L (en) 1985-10-30
FI851686L (fi) 1985-10-31

Similar Documents

Publication Publication Date Title
AU584611B2 (en) Kit for use in the treatment of osteoporosis
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
ES2011120A6 (es) Forma de dosificacion para tratar las enfermedades cardiovasculares.
IL82216A0 (en) Synergistic combinations of amantadin and selegilin and their preparation
JPS6470411A (en) Drug for oral use
MX9602442A (es) Un tratamiento con fluoroquinolona a dosis unica elevada.
ES8801243A1 (es) Procedimiento para la obtencion de medicamentos que contienen 1-heteroaril-4--aril-pirazolin-5-onas.
EP0296539A3 (de) Vorrichtung zur Zahnwiederherstellung aus Verbundwerkstoffen unter Verwendung einer Matrize aus Verbundwerkstoffen
ZA923935B (en) New 2-amino-5-cyano-1,4-dihydropyridines,processes for their preparation and their use in medicaments
EP0177356A3 (en) Method for treatment of antidiuresis
JO1521B1 (en) Amino Propene compounds are substituted amides, practical for their preparation, the agents they contain, their use, and new intermediate compounds produced in the preparation process.
UA43337C2 (uk) Гормональний засіб для лікування вугрів
PH24445A (en) Pharmaceutical compositions for the therapy of cerebropathies on functional and organic base
AU581736B2 (en) Fungicides and plant-growth controlling agents
GR900300082T1 (en) Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine
AU551108B2 (en) Analgesic potentiation of zomepirac with butorphanol
GR3022935T3 (en) Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutritients
ZA864717B (en) Terguride as a geriatric agent
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
ZA815094B (en) Novel peptide
BR8502016A (pt) Semeadeira manual(plantadeira)que pode ser acionada por uma unica mao
UA10995C2 (uk) Препарат "hейтрам" для лікуваhhя hеоhатальhих діарей у телят
GR3003773T3 (de)
UA8596A1 (uk) Субстракт для вирощуваhhя істівhого гриба гливи звичайhої
MY102847A (en) Contrast enhancement layer compositions, alkylnitrones, and use.